15 November 2020
Limaca Medical, announced it has closed $1.25 million of a $1.5 million round to complete first-in-human procedures, post-market clinical studies, and obtain regulatory approvals.
Limaca raised $1.25 million from Trendlines, Agriline (ultimately owned by a trust of which Vincent Tchenguiz is a discretionary beneficiary ), Limaca Chairman and medical device industry veteran Carl Rickenbaugh, and a private investor.
The Precision™ biopsy device developed by Limaca deploys an automated revolving needle to acquire high-quality core tissue for histopathology and advanced genetic profiling. The Precision device makes it possible to acquire biopsy tissue samples at ten times greater procedural efficiency with less trauma than today’s endoscopic standard of care for greater diagnostic accuracy and patient-specific treatment to achieve better clinical outcomes.
News of this investment appeared in Yahoo Finance, CTech and GeekTime.
We designed Precision to improve upon endoscopic biopsies and make a substantial leap forward in this critical diagnostic procedure to advance precision treatment and achieve superior outcomes for cancer patients.
Limaca Medical CEO Assaf Klein
To date, 10 patients have been enrolled in Limaca’s FIH study at the Rambam Health Care Campus in Israel. The FIH study compares Limaca’s Precision to standard of care EUS biopsy devices. Results have demonstrated excellent ease of use, safety, and improved sample capture. Precision exceeded all clinical expectations for endoscopic biopsy while demonstrating clear safety in our cases.
Director, Invasive Endoscopy Unit, Rambam Healthcare Campus, Professor Iyad Khamaysi, and a Limaca founder
See More News
Escala Secures $4.5M in Funding to Accelerate Global Expansion of Its FDA-Approved Medical Device
Co-financing by the EIC Fund to ramp up women’s health solution to POP
Phytolon Secures Funding from Rich Products Ventures to Bring Natural Food Colors to Market
